Phenotypic Test Identifies Antibiotic-Resistant Bacterial Infections
|
By LabMedica International staff writers Posted on 04 Dec 2018 |
|
Image: The BD Phoenix identification and susceptibility combo panels (Photo courtesy of Becton, Dickinson and Company).
Carbapenemase-producing organisms (CPO) are gram-negative bacteria that are resistant to the carbapenem class of antibiotics, which are commonly used for severe or high-risk bacterial infections. Mortality related to CPO infection is quite high around the world, with reported rates from 22% to 72%.
A CPO detect test, which offers results in less than 36 hours, is expected to replace time-consuming, manual detection that can take up to 96 hours for results. The CPO detection test will be offered as part of the BD Phoenix gram-negative panels, which already use susceptibility testing to expose bacteria from a specific patient's infection to a variety of potential treatments or candidates to gauge how they respond.
The BD Phoenix CPO detect test has gained US Food and Drug Administration clearance. The test may help hospitals contain the spread of antimicrobial resistance (AMR) by shortening the time it takes to detect CPOs, thereby enabling the earlier implementation of infection control procedures and the initiation of appropriate antibiotic therapies designed for treating these infections.
Kenneth Thomson, PhD, clinical professor of Pathology and Laboratory Medicine at the University of Louisville School of Medicine, said, “The BD Phoenix CPO detect test is a completely new type of phenotypic test, and its range of automation and diagnostic capabilities is unmatched by all other currently marketed tests. It represents a significant advance in meeting an important clinical need for rapid detection of CPOs.”
Steve Conly, vice president and general manager of Microbiology for BD Diagnostic Systems, said, “The BD Phoenix CPO detect test gives laboratories an accurate and cost-effective method to rapidly identify CPOs and support patient management. Along with the BD Phoenix M50 instrument, this automated first-to-market, phenotypic test to detect CPOs, using the BD Phoenix system, expands the BD portfolio of solutions for identification and antimicrobial susceptibility testing and is another example of the company's commitment to providing solutions that help addressing the global burden of antimicrobial resistance.”
Related Links:
University of Louisville School of Medicine
A CPO detect test, which offers results in less than 36 hours, is expected to replace time-consuming, manual detection that can take up to 96 hours for results. The CPO detection test will be offered as part of the BD Phoenix gram-negative panels, which already use susceptibility testing to expose bacteria from a specific patient's infection to a variety of potential treatments or candidates to gauge how they respond.
The BD Phoenix CPO detect test has gained US Food and Drug Administration clearance. The test may help hospitals contain the spread of antimicrobial resistance (AMR) by shortening the time it takes to detect CPOs, thereby enabling the earlier implementation of infection control procedures and the initiation of appropriate antibiotic therapies designed for treating these infections.
Kenneth Thomson, PhD, clinical professor of Pathology and Laboratory Medicine at the University of Louisville School of Medicine, said, “The BD Phoenix CPO detect test is a completely new type of phenotypic test, and its range of automation and diagnostic capabilities is unmatched by all other currently marketed tests. It represents a significant advance in meeting an important clinical need for rapid detection of CPOs.”
Steve Conly, vice president and general manager of Microbiology for BD Diagnostic Systems, said, “The BD Phoenix CPO detect test gives laboratories an accurate and cost-effective method to rapidly identify CPOs and support patient management. Along with the BD Phoenix M50 instrument, this automated first-to-market, phenotypic test to detect CPOs, using the BD Phoenix system, expands the BD portfolio of solutions for identification and antimicrobial susceptibility testing and is another example of the company's commitment to providing solutions that help addressing the global burden of antimicrobial resistance.”
Related Links:
University of Louisville School of Medicine
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
All-in-One Molecular System
AIO M160
Steam Sterilizer
Hi Vac II Line
Latest Microbiology News
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
- H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read more
Molecular Diagnostics
view channel
Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
Vesicular and pustular skin lesions can stem from multiple viral pathogens, complicating timely diagnosis and management. Sequential single-pathogen testing can miss infections when the causative agent... Read more
Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
Radium-223 dichloride is a bone-targeted radiopharmaceutical therapy that improves overall survival and quality of life for many patients with metastatic castration-resistant prostate cancer (mCRPC), but... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more
Pathology
view channel
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read more
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
Bruker Corporation has acquired the DISQVER clinical metagenomics platform from Noscendo GmbH, expanding its next-generation sequencing infection detection portfolio. Following the acquisition, DISQVER... Read more
